Paradigm Biopharmaceuticals Ltd. · ASX:PAR

Paradigm Biopharmaceuticals — Shareholder Meeting (October 2015)

17 slides from Paradigm Biopharmaceuticals's shareholder meeting presentation, Oct 30, 2015

1. Slide 1: Annual General Meeting of Shareholders

   For personal use only Paradigm BioPharmaceuticals Annual General Meeting of Shareholders OCTOBER 2015

2. Slide 2: Disclaimer

   Disclaimer For personal use only This presentation was prepared by Paradigm BioPharmaceuticals Ltd known as “Paradigm” or “the Company”), in order to indicate on a preliminary basis, the feasibility of a possible transaction or transactions. This presentation is incomplete without reference to, and

3. Slide 3: Background - Paradigm repurposing Pentosan Polysulfate Sodium

   Background - Paradigm repurposing Pentosan Polysulfate Sodium For personal use only Repurposing means finding new indications for old drugs. Drug repurposing provides advantages of more likelihood of regulatory success, faster time to revenues and much less expensive compared to new drug developme

4. Slide 4: Board of Directors

   Board of Directors For personal use only Mr Graeme Kaufman, Non-Executive Chairman (Bsc, MBA) – Graeme was previously Chief Financial Officer at CSL Limited and Executive Vice President of Corporate Finance at Mesoblast Limited. Currently Chairman of Bionomics Limited and IDT Limited and Non-Exec Di

5. Slide 5: Appointment of key executives

   Appointment of key executives For personal use only Dr Claire Kaufman – Operations Manager Dr Claire Kaufman, is an experienced Veterinary Surgeon. After 8 years of clinical veterinary and organisational experience in private practice and large animal welfare organisations, Claire pursued work in pr

6. Slide 6: Appointment of key employees (cont.)

   Appointment of key employees (cont.) For personal use only Lenna Tye - Senior Bookkeeper. Helen Hu - Accountant. Kevin Hollingsworth – CFO and Company Secretary. 6 ©2015 PARADIGM BIOPHARMACEUTICALS

7. Slide 7: Appointment of key consultants – bone marrow lesions

   Appointment of key consultants – bone marrow lesions For personal use only Prof Graeme Jones: University of Tasmania. Prof Flavia Cicuttini: Monash University. Dr Andrew Potter and Dr Mathew Liptak: Sports medicine and orthopaedic surgeon providing clinical advice. Prof David Findlay: Adelaide Unive

8. Slide 8: Appointment of key consultants – allergic rhinitis

   Appointment of key consultants – allergic rhinitis For personal use only Prof Jonas Erjefält: Lund University Prof Xiangdong: Shanghai University Dr Janet Rimmer: Woolcock Institute Prof Paul Young: Woolcock Institute Dr Judith Jaeger: US based clinical consultant 8 ©2015 PARADIGM BIOPHARMACEUTICALS

9. Slide 9: Key commercial partners

   Key commercial partners For personal use only Bene pharmaChem (Germany). Supplier of API (pentosan polysulfate sodium). Manufacturing facility is FDA approved. Bene to also provide analytical support to PAR. Bene to provide finished product (ampoules for bone marrow lesion study). Aptar (Germany). S

10. Slide 10: Bone Bruising, Bone Marrow Edema or Bone Marrow Lesions

    Bone Bruising, Bone Marrow Edema or Bone Marrow Lesions For personal use only 10 ©2014 PARADIGM BIOPHARMACEUTICALS

11. Slide 11: Bone Marrow Lesions - post acute injury

    Bone Marrow Lesions - post acute injury For personal use only 11 ©2014 PARADIGM BIOPHARMACEUTICALS

12. Slide 12: PPS, in peer reviewed scientific publications, has been shown to:

    PPS, in peer reviewed scientific publications, has been shown to: For personal use only • Inhibit the cartilage degrading enzymes which are upregulated post-acute injury; • Have anti-inflammatory effects including blocking the effects of the pro- inflammatory cytokine TNF and pro-inflammatory interl

13. Slide 13: Open label clinical trial investigating the role of PPS in acute anterior cruciate ligament injuries

    Open label clinical trial investigating the role of PPS in acute anterior crucicate For personal use only ligament injuries Background: “Follow-up of people who suffered knee ligamentous and meniscal injuries demonstrated that they had a 10-fold increased risk of OA as compared with those who did no

14. Slide 14: Allergic rhinitis

    Allergic rhinitis For personal use only Allergic rhinitis is a very common condition. Characterised by blocked nose, itchy runny nose and sneezing. Affects more than 40 million people in the USA. Global Market size (antihistamines and nasal corticosteroids) $US 11bn. In animal model, PPS has proven

15. Slide 15: Two year expenditure program

    2 year expenditure program For personal use only Paradigm completed an IPO financing in August 2015. The proceeds from the Offer will be used to complete: - Complete open label Phase 2 clinical trial in 40 ACL patients; - Commence Phase 1 clinical trial in 20 patients and commencement of open label

16. Slide 16: Milestones – next months

    Milestones – next 12 months For personal use only  US Patent granted for treatment of Bone Marrow Lesions with PPS; • Ethics approval for open label pilot phase 2 clinical trial - bone marrow lesions; • First patient treated under open label pilot phase 2 clinical trial – bone marrow lesions; • Fir

17. Slide 17: Thank you and questions

    For personal use only Thank you and questions

Paradigm BioPharmaceuticals — Shareholder Meeting (October 2015) on 6ix